Pricing Log in Create free account
Friday 6 November 2026 Export BBIO’s income statement to Excel — free account

BridgeBio Pharma, Inc.

BBIO Healthcare Biotechnology

BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024.

Revenue
+192.6%
EPS
+55.8%
Free cash flow
+60.5%
Total debt
+4.21%

Quarter to September 2026, against a year earlier

74.39 0.12 +0.16%
Market cap
$14.5B
P/E
0.0×
Fwd P/E
−27.5×
Dividend yield
—
F-score
3/9
Altman Z
−3.45
Beneish M
8.17
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BridgeBio Pharma, Inc. (BBIO) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 5 added · 5 removed · 39 modified
P2I1A: 3 added · 51 modified 		Receivables outpacing revenue
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 31, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 13, 2026 1.01 Entry into a material definitive agreement; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Aug 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 22, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 1, 2026 1.01 Entry into a material definitive agreement; 3.02 Unregistered sales of equity securities; 3.03 Material modification of shareholders' rights; 5.03 Amendments to the articles or bylaws; change in fiscal year; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jun 22, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
8-K May 27, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 12, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 7, 2026 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 8.01 Other events
8-K Mar 30, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 129 added · 73 removed · 75 modified
1A: 21 added · 30 removed · 130 modified
7: 52 added · 33 removed · 72 modified
8-K Feb 24, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 12, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 14, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 29, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 27, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 20, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 13, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 12, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 22, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.